ClinVar Miner

Submissions for variant CYP2C19*4A (rs28399504)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Clinical Pharmacogenetics Implementation Consortium RCV000782432 SCV000920955 drug response CYP2C19: no function practice guideline curation
PharmGKB RCV000211166 SCV000268285 drug response clopidogrel response - Efficacy 2015-10-28 reviewed by expert panel curation PharmGKB Level of Evidence 1A: Annotation for a variant-drug combination in a CPIC or medical society-endorsed PGx guideline, or implemented at a PGRN site or in another major health system.
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000383294 SCV000331712 other not provided 2015-12-28 criteria provided, single submitter clinical testing
GeneDx RCV000383294 SCV000971805 likely benign not provided 2018-03-26 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
OMIM RCV000018399 SCV000038681 drug response Mephenytoin, poor metabolism of 1998-01-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.